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Background: To translate and validate the Chinese version of the Quality Of Life Radiation Therapy Instrument and
the Head & Neck Module (QOL-RTI/H&N), a disease-specific scale to measure quality of life (QOL) for patients with
head and neck cancer (HNC) who received radiotherapy.
Methods: The QOL-RTI/H&N was translated and validated according to the standard process: a translation and back-
translation procedure, pilot testing and a validation study. HNC patients were enrolled from the Cancer Center of Sun Yat-sen
University and assessed using the QOL-RTI/H&N, QLQ-C30 and QLQ-H&N35. Reliability (internal consistency reliability, split-half
reliability and test-retest reliability), validity (content validity, construct validity, criterion validity and discriminant validity),
and responsiveness analysis were performed to evaluate the psychometric characteristics of the QOL-RTI/H&N.
Results: A total of 238 patients (99.2%) completed the questionnaire. Item RTI23 had 16.0% missing data. Other items
had low percentages of missing data (0.4% or 0.8%) or no missing data. The average time to finish the scale was
9.8 minutes. Cronbach's alpha of the domains ranged from 0.41 to 0.77. The split-half reliability coefficients ranged from
0.43 to 0.77. All of the intra-class correlation coefficients were equal to or greater than 0.8. All of the item-own domain
correlation coefficients were greater than those of the item-other domain. Confirmatory factor analysis showed that
Comparative Fit Index, Normed Fit Index and Non-Normed Fit Index were equal to 1.00. Root Mean Square Error of
Approximation was 0.01, with 90% CI (0.00, 0.10). The domain scores of the QOL-RTI/H&N were significantly correlated
with those of the QLQ-C30 or QLQ-H&N3. All domain scores of patients in different radiotherapy stages were statisti-
cally significant (P < 0.05), apart from the speech domain.
Conclusions: The Chinese version of the QOL-RTI/H&N is a valid, reliable and responsive scale to measure QOL in HNC
patients and can be used to assess the effects of radiotherapy treatment on these patients.
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Head and neck cancer (HNC) is the sixth most common
cancer worldwide [1]. According to data from the Inter-
national Agency for Research on Cancer, the number of
HNC patients (including lip, oral cavity, esophagus, lar-
ynx, nasopharynx and other pharynx) was estimated to* Correspondence: gmfsums@126.com; liulizh@sysucc.org.cn
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unless otherwise stated.be more than 1,140,000, with incidence and mortality
rates at 15.1 and 10.0 per 100,000, respectively, in 2012
[2]. Nasopharyngeal cancer is one of the most prevalent
HNCs in China, and is much more prevalent than in the
rest of the world [3].
Radiotherapy (RT) is the main treatment for HNC pa-
tients. However, RT treatment not only kills the tumor
cells, but also injures the normal local tissues [4,5]. HNC
patients receiving RT treatment are subjected to numerous
of adverse effects, such as dry mouth, thick saliva, and diffi-
culties in opening the mouth, swallowing and speaking. All
of these adverse effects drastically reduce their quality oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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such as QOL and Patient-Reported Outcomes (PROs),
have attracted more and more attention in recent years [6].
The common scales to evaluate QOL in HNC patients
include the EORTC Quality of Life Questionnaire - Core
Questionnaire (QLQ-C30) and the Head and Neck Can-
cer Module (QLQ-H&N35) [7-11], the Functional As-
sessment of Cancer Therapy - General (FACT-G) and
the Head & Neck Scale (FACT-H&N) [12,13], the Qual-
ity Of Life Radiation Therapy Instrument and Head &
Neck Module (QOL-RTI/H&N) [14,15], the Head and
Neck Radiotherapy Questionnaire (HNRQ) [16], the
University of Washington Quality Of Life questionnaire
(UWQOL) [17], the Quality of Life Instrument for Head
and Neck Cancer (QL-H&N) [18], the Quality of Life
Questionnaire for advanced HNC patients (QLQ) [19],
and the University of Michigan Head and Neck Quality
Of Life (HNQOL) [20]. Among these scales, only the
HNRQ, QLQ-H&N35 and QOL-RTI/H&N were specif-
ically designed to evaluate the QOL of HNC patients re-
ceiving radiotherapy [14-16]. The HNRQ only focuses
on the side effects of RT treatment and was not recom-
mended for independent use [16]. The QLQ-H&N35
has been translated into Chinese, and has been reported
as a valid, reliable and responsive scale [21]. The QOL-
RTI/H&N was developed to evaluate QOL in HNC pa-
tients after RT treatment by researchers in the Division
of Radiation Oncology of the University of South Florida.
The QOL-RTI/H&N already had the versions in English,
Japanese, and German, as well as a version developed spe-
cifically for Hong Kong [14,15,22-24]. All versions showed
good validity and reliability.
The aim of this study was to develop the Chinese
(Mainland China) version of the QOL-RTI/H&N. We
translated and back-translated the English version, and
adapted it linguistically and culturally in China. We doc-
umented the translation, back-translation, cultural adap-
tation and psychometric testing of the scale.
Methods
Translation and back-translation procedure
The English version of the QOL-RTI/H&N was trans-
lated according to the standard process for translating
instruments [25-28]. Permission to use the QOL-RTI/
H&N was obtained from the original authors. Two bilin-
gual (Chinese and English) native speakers translated the
original version into Chinese independently. The transla-
tion coordinator (one of the authors) compared the two
Chinese versions and reconciled any differences. At last,
the team, including the two translators, three radiother-
apy doctors, two radiotherapy nurses, two QOL experts
and four H&N cancer patients, compiled the Chinese
version and chose the most appropriate wording for
clarity and similarity to the original. The final Chineseversion was formed after the team discussed culturally
problematic issues.
The Chinese version was translated back into Eng-
lish by two separate translators independently, neither
of whom had previously seen the scale. The two
back-translated versions were also coordinated and
discussed by the team. The changing of sentences and
wordings were approved to obtain the results of the
back-translated version.
Pilot testing
Pilot testing was used to assess cultural adaptation and
content validity of the Chinese version of the QOL-RTI/
H&N. All of the items were tested in a convenience sam-
ple of 10 HNC patients from different educational levels.
The time taken to complete the QOL-RTI/H&N was less
than 12 min. Problematic items were revised according to
the comments of the patients. Cultural adaptation was
summarized and content validity was assessed.
The pilot testing found that most items in the Chinese
version and the original version had similar meanings.
Only a few were revised. For example, HNC patients re-
ported that Item 17 (IRT17) “support from God” was
difficult to understand. So Item IRT17 was revised as “I
get support from faith or religion, for example, Bud-
dhism, Taoism, etc.” The patients reported that they
were embarrassed to answer Item IRT23 “My sexual ac-
tivity is satisfactory”. However, no appropriate sentence
could be found to replace it, so the original sentence
remained.
Validation study
A cross-sectional study was conducted to measure the
reliability, validity and responsiveness of the scale. The
patients pathologically diagnosed with HNC in the Can-
cer Center of Sun Yat-sen University were enrolled from
July 1st to September 15th in 2012. The patients who
had other types of cancer and those who were illiterate
were excluded. The written permission and approval for
this study was obtained from the committee board in
the Cancer Center of Sun Yat-sen University.
The investigators were medical graduate students who
received specific training. They explained the aim of our
study to the HNC patients. After obtaining informed con-
sent from the patients, they gave each patient a question-
naire to complete by self-administration, including a
socio-demographic sheet, and the QOL-RTI/H&N, QLQ-
C30 and QLQ-H&N35. The socio-demographic sheet cov-
ered age, gender, marital status, monthly income, dialect,
current work status, types of disease, other chronic dis-
ease, as well as the time of first radiotherapy. According to
the time of first radiotherapy, RT stages were divided into
5 groups: before RT, under RT, ≤1 year after RT, ~5 years
after RT, and >5 years after RT. If patients did not fully
Table 1 Characteristics of the patients (n = 238)
Number of patients (%)








≤2000 Yuan 87 (36.6)
~5000 Yuan 119 (50.0)
















≤ 1 year after 57 (23.9)
~5 years after 50 (21.0)
>5 years after 41 (17.2)
Non-nasopharynx included oral, oropharyngeal, hypopharyngeal, salivary
gland, laryngeal and paranasal cancer. RT: radiotherapy.
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plained them clearly or used other understandable words
with the same meaning. At last, the investigators made ef-
forts to help the patients complete the questionnaire.
All of the HNC patients were required to fill in the
QOL-RTI/H&N within 24–48 hours. The patients who
were newly diagnosed with HNC for the first time were
also required to finish the scale within 28 ± 2 days of RT
treatment.
Questionnaires
The QOL-RTI/H&N consists of the QOL-RTI and the
H&N module. The QOL-RTI is a general scale with 24
items, assessing components of function, emotion, fam-
ily/socio-economics (family for short) and general (over-
all) QOL [14]. The H&N module consists of domains
related to pain, appearance, speech, swallowing and
chewing (swallow for short), saliva and mucous (saliva
for short), taste, and cough [15]. Each item is rated on a
0–10 Likert type scale. The scores for all items in each
domain are summed and average to yield a single score.
A higher score indicates a better QOL.
Statistical analyses
The analyses consisted of the description of the characteris-
tics, assessment of item quality, reliability analysis, validity
analysis and responsiveness analysis. Most of the statistical
analyses were done with Windows SPSS 17.0 (SPSS Inc,
Chicago, IL). Confirmatory factor analysis (CFA) was con-
ducted using Lisrel software (Version 8.7) [29].
Item quality was assessed using mean, standard devia-
tion (SD), missing data, lowest (floor) and highest (ceiling)
scores. Reliability analysis included internal consistency reli-
ability, split-half reliability, and test-retest reliability. Internal
consistency reliability was evaluated using Cronbach's alpha
value. Split-half reliability was assessed by Pearson's cor-
relation coefficients between two halves of the items.
Test-retest reliability coefficients were calculated by the
intra-class correlation coefficient (ICC), along with 95%
confidence interval (CI) of the two scores within 24–48
hours. The short test-retest time interval (24 ~ 48 hours)
was chosen for the following reasons. (1) All of the HNC
patients enrolled in the study were being treated with RT.
The treatment had an obvious influence on QOL, particu-
larly when the time interval was long. (2) Marx et al. re-
ported no significant differences for the test-retest reliability
of the two time intervals (2 days and 2 weeks) [30].
Validity analysis included content validity, construct val-
idity, criterion validity, and discriminant validity. Content
validity was compared using the item-own domains (the
item and its own domain) and the item-other domains (the
item and other domains) correlation coefficients. If the cor-
relation coefficient of item-own domains was greater than
that of item-other domains, then the item had goodcontent validity. CFA was used to measure the construct
validity and assess how well the data fit the theoretical
model [31-33]. Comparative Fit Index (CFI), Normed Fit
Index (NFI), Non-normed Fit Index (NNFI), Root Mean
Square Error of Approximation (RMSEA) and its 90% CI
were all calculated. Values of CFI, NFI and NNFI equal to
or greater than 0.9 were considered to have an adequate fit,
and those near to 1 as having a good fit [34]. RMSEA less
than 0.05 indicated a good fit [35,36]. Criterion validity was
obtained by calculating the Pearson correlation coefficients
of the domain scores between the QOL-RTI/H&N and the
QLQ-C30 or QLQ-H&N35. Discriminant validity was mea-
sured by comparing the QOL of patients in different RT
stages, which were analyzed by analysis of variance
(ANOVA). If the QOL of the patients in different RT stages
Table 2 Mean, SD, missing data, floor and ceiling scores of each item (n = 238)
Item Mean SD Missing(%) Floor(%) Ceiling(%) Item Mean SD Missing(%) Floor(%) Ceiling(%)
RTI1 6.55 3.04 0.0 3.4 19.3 RTI21 7.23 2.39 0.0 0.4 26.1
RTI2 6.68 2.94 0.0 0.4 21.4 RTI22 6.97 2.94 0.0 0.4 25.2
RTI3 5.97 3.20 0.0 1.7 16.4 RTI23 5.84 2.75 16.0 3.4 11.8
RTI4 7.67 3.15 0.0 5.5 39.1 RTI24 6.79 2.74 0.0 1.3 16.4
RTI5 5.28 3.08 0.0 5.5 12.2 RTI25 6.53 1.93 0.8 1.3 5.9
RTI6 6.44 3.32 0.0 7.6 20.6 RTI26 7.41 3.15 0.0 4.2 34.0
RTI7 3.99 3.35 0.0 18.1 7.1 RTI27 6.95 3.36 0.0 6.7 33.2
RTI8 5.31 2.75 0.0 6.3 7.1 RTI28 3.79 3.50 0.0 10.1 13.4
RTI9 5.81 3.44 0.4 6.3 21.8 RTI29 3.55 3.31 0.4 15.5 9.7
RTI10 7.78 2.22 0.0 0.4 30.7 RTI30 4.44 3.55 0.4 8.8 18.1
RTI11 7.99 2.33 0.0 1.3 31.9 RTI31 6.00 3.53 0.0 5.5 22.7
RTI12 8.16 2.30 0.4 1.3 37.8 RTI32 6.71 3.16 0.0 5.5 23.5
RTI13 5.13 3.36 0.0 9.7 15.5 RTI33 7.78 2.83 0.0 3.4 33.6
RTI14 5.59 3.61 0.8 12.6 22.7 RTI34 7.65 2.75 0.0 2.5 36.1
RTI15 7.01 2.37 0.0 0.8 22.3 RTI35 5.59 3.16 0.0 7.1 14.3
RTI16 8.71 1.87 0.4 1.3 50.4 RTI36 7.47 2.48 0.0 2.5 26.1
RTI17 9.41 1.34 0.0 0.8 72.7 RTI37 6.82 3.24 0.0 5.9 28.2
RTI18 2.44 3.20 0.0 47.1 7.1 RTI38 5.68 3.21 0.0 5.9 18.1
RTI19 7.35 3.20 0.0 2.9 37.8 RTI39 8.95 2.32 0.0 2.1 67.2
RTI20 7.14 2.05 0.0 0.8 14.3
Mean score: 0 (worst QOL) to 10 (best QOL). RTI1: the first item of the QOL-RTI/H&N scale, etc. SD: standard deviation.
Chen et al. Health and Quality of Life Outcomes 2014, 12:51 Page 4 of 9
http://www.hqlo.com/content/12/1/51was significantly different, then the scale had good discrim-
inant validity.
Paired samples t-test was used to analyze the QOL
changes over time for the patients receiving RT treat-
ment the first time. If the QOL had improved or de-
creased significantly after treatment, it meant that the
scale had good responsiveness. Effect size was calculated





Mean ± SD a^ Split-ha
coefficie
Function 9 (0.6, 10.0) 6.50 ± 1.83 0.77 0.72
Emotion 7 (1.7, 10.0) 6.22 ± 1.38 0.49 0.53
Family 6 (4.0, 10.0) 6.83 ± 1.24 0.41 0.43
General 3 (1.7, 10.0) 6.97 ± 1.70 0.71 0.68
Pain 2 (0.0, 10.0) 7.18 ± 2.93 0.77 0.77
Swallow 5 (1.2, 10.0) 6.90 ± 1.91 0.67 0.65
Saliva 3 (0.0, 10.0) 3.93 ± 2.82 0.74 0.70
Appearance 1 (0.0, 10.0) 6.71 ± 3.16 NA NA
Speech 1 (0.0, 10.0) 7.78 ± 2.83 NA NA
Taste 1 (0.0, 10.0) 6.00 ± 3.53 NA NA
Cough 1 (0.0, 10.0) 7.65 ± 2.75 NA NA
a^Cronbach's alpha value. NA meant no value, due to one single item.score. Effect size greater than 0.5 was considered to be
clinically significant [37].
Results
A total of 240 patients were enrolled in the study. Two
patients refused to complete the questionnaire. Finally,
238 (99.2%) patients completed the questionnaire. Four







0.82(0.70, 0.89) 0.50 ~ 0.71 0.02 ~ 0.44
0.90(0.84, 0.94) 0.44 ~ 0.64 0.086 ~ 0.41
0.80(0.67, 0.88) 0.42 ~ 0.65 0.04 ~ 0.32
0.88(0.79, 0.93) 0.79 ~ 0.83 0.11 ~ 0.55
0.87(0.78, 0.92) 0.89 ~ 0.91 0.17 ~ 0.44
0.93(0.88, 0.96) 0.50 ~ 0.73 0.02 ~ 0.44
0.89(0.82, 0.94) 0.79 ~ 0.84 0.08 ~ 0.41
0.87(0.75, 0.93) 1.000 0.14 ~ 0.40
0.89(0.80, 0.94) 1.000 0.06 ~ 0.15
0.94(0.89, 0.96) 1.000 0.08 ~ 0.41
0.87(0.76, 0.93) 1.000 0.15 ~ 0.42
Figure 1 The CFA structure diagram of the QOL-RTI scale.
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meaning of the questionnaire. The age ranged from 21.7
to 78.8, with a mean age of 46.5. There were 176 male
patients and 62 females. 95.4% of the patients were mar-
ried. 64.3% of the patients were Cantonese. 71.4% were
patients with nasopharyngeal carcinoma (Table 1).
The scores of all the items ranged from 0 to 10
(Table 2). Item RTI17 scored the highest (9.41), while
item RTI18 scored the lowest (2.44). Item RTI23 had
16.0% missing data. Items RTI9, RTI12, RTI14, RTI16,
RTI25, RTI29 and RTI30 had low missing data (0.4% or
0.8%). Other items did not have any missing data. Item
RTI18 showed 47.1% of responses at floor. Item RTI17,
RTI39 and RTI16 showed 72.7%, 67.2%, and 50.4% of re-
sponses at ceiling, respectively.
The mean score of the saliva domain was 3.93, and
mean scores of other domains were higher than 6.00
(Table 3). Cronbach's alpha values of all domains wereFigure 2 The domain scores in different RT stages (mean ± SE, *: signbetween 0.41 (family) and 0.77 (pain). The split-half co-
efficients of all domains ranged from 0.43 (family) to
0.77 (pain). The test-retest coefficients of all domains
were equal to or greater than 0.8 (0.80 ~ 0.94). All item-
own domain correlation coefficients exceeded 0.4, which
were greater than those of the item-other domain.
The results of the CFA showed that normal theory
weighted least squares Chi-Square of the model was
equal to 2.11 (P = 0.35 > 0.05). CFI, NFI and NNFI were
equal to 1.00. RMSEA was 0.01, with 90% CI (0.0, 0.10)
(Figures 1 and 2).
Criterion validity was tested by comparing the QOL-
RTI/H&N with the QLQ-C30 and QLQ-H&N35. There
were positive correlation coefficients (0.28 to 0.45) be-
tween QOL-RTI domain scores and corresponding
scores of the QLQ-C30 (Table 4). The pain, swallow,
speech, and cough domains in the H&N module had sig-
nificantly negative correlations with those of the QLQ-
H&N35 (P <0.05).
All domain scores of patients in different RT stages
were significantly different (P <0.05), except for those of
the speech domain (Table 5, Figure 2). The patients who
were receiving RT treatment (under) generally had the
lowest QOL scores, while those who had not received
RT treatment (before) had higher QOL scores. No statis-
tically significant differences emerged for any of the
QOL domains when examined by gender, tumor site, or
other disease (see Additional file 1).
Fifty patients who had received RT treatment for the
first time were enrolled to test the responsiveness of the
scale over time. After 28 days of treatment with RT, all do-
main scores decreased (Table 6). The change in scores for
all domains were significantly different, with effect sizesificantly different).
Table 4 Criterion validity of the QOL-RTI/H&N (n = 238)
QOL-RTI/H&N QLQ-C30, QLQ-H&N35 Correlation coefficient
Function PF of QLQ-C30 0.34*
Emotion EF of QLQ-C30 0.32*
Family SF of QLQ-C30 0.28*
General QL of QLQ-C30 0.45*
Pain Pain of QLQ-H&N35 −0.56*
Swallow Swallow of QLQ-H&N35 −0.32*
Speech Speech of QLQ-H&N35 −0.35*
Cough Cough of QLQ-H&N35 −0.53*
PF: Physical functioning; EF: Emotional functioning; SF: Social functioning; QL:
Global health. *meant P < 0.05. The Saliva, appearance, and taste domains did
not have criterion validity.
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Except for emotion, family, general and speech domains,
the effect sizes of other domains were greater than 0.5.
The average time to finish the scale was 9.8 ± 4.3 mi-
nutes, ranging from 7.2 to 13.6 minutes. Four patients
reported that the 0–10 Likert style was difficult for them
to understand. They were not able to clearly discrimin-
ate the 0–10 Likert style. They preferred the 5-Likert
style with an explanation.
Discussion
With the help of RT treatment, HNC patients survive
for a longer time. However, the complications and side
effects of RT treatment seriously affect their QOL. The
insufficiency of a specific radiotherapy scale measuring
the QOL of Chinese HNC patients led us to translate
and validate the QOL-RTI/H&N.
The QOL-RTI/H&N had good content validity. The
WHOQOL group proposed that QOL incorporates the
physical health, psychological state, social relationships, and
general relationships of the individual to salient features of
the environment, independence and belief [38,39]. The
QOL-RTI is structurally made up of function, emotion,Table 5 Domain scores (Mean ± SD) in different RT stages
Before (n = 50) Under (n = 40) ≤ 1 year after RT (n = 5
Function 7.90 ± 1.70 4.91 ± 1.68 6.31 ± 1.58
Emotion 7.03 ± 1.55 6.00 ± 1.46 6.08 ± 1.27
Family 7.69 ± 1.46 6.30 ± 1.04 6.79 ± 1.16
General 8.13 ± 1.56 6.79 ± 1.47 7.04 ± 1.65
Pain 8.08 ± 2.59 4.66 ± 3.25 6.73 ± 3.03
Swallow 8.00 ± 2.12 5.99 ± 1.81 6.41 ± 1.56
Saliva 5.24 ± 3.16 3.07 ± 2.13 2.84 ± 1.93
Appearance 7.56 ± 3.27 5.72 ± 2.31 6.33 ± 2.76
Speech 8.62 ± 2.38 7.39 ± 2.96 7.62 ± 2.81
Taste 7.40 ± 3.40 3.41 ± 3.54 5.67 ± 3.44
Cough 9.02 ± 1.89 6.44 ± 3.09 7.39 ± 2.87family, and general domains, which are the main domains
defined by the WHOQOL group. The H&N module con-
sists of 7 symptom domains (pain, appearance, speech,
swallowing, saliva, taste, and cough). It includes the most
important clinical aspects characterizing specific aspects of
QOL for HNC patients, such as “I have pain in my mouth,”
“I have pain in my throat,” “I have a normal amount of sal-
iva,” “My saliva is too thick,” and “I can swallow all food
without difficulty”. These items could truly reflect the suf-
fering of HNC patients receiving RT treatment. Addition-
ally, all item-own domain correlation coefficients were
greater than that of the item-other domain.
The Chinese version of the QOL-RTI/H&N had good re-
liability (internal consistency reliability, split-half reliability
and test-retest reliability). The QOL-RTI/H&N had moder-
ate or high values for Chronbach's alpha (0.41-0.77). The
emotion and family domains had the lowest values. This re-
sult may stem from some inconsistent items in these do-
mains, such as the appearance and financial items in the
emotion domain, and the independence item in the family
domain. A similar result was observed in the Hong Kong
version of the scale [22]. They reported that Cronbach's
alpha values in other domains were greater than 0.7, while
those of emotion and family domains were 0.58 and 0.61,
respectively. Our results showed that all domains had mod-
erate or high split-half reliability coefficients (0.43-0.77),
and had high test-retest reliability coefficients (0.80-0.94),
which is consistent with previous studies [15,22,24]. It was
reported that test-retest reliability coefficient of the scale
was 0.87 for the German version [24], and was 0.92 for the
Hong Kong version [22].
The Chinese version of the QOL-RTI/H&N had good val-
idity (construct validity, criterion validity, and discriminant
validity), as well. CFI, NFI and NNFI of the QOL-RTI were
equal to 1.00, and RMSEA was 0.01, with a 90% CI (0.0,
0.10). All indices indicated good construct validity for the
scale. Theoretically similar domains of the QOL-RTI/H&N
and the QLQ-C30 or QLQ-H&N35 were significantly7) ~5 years after RT (n = 50) >5 years after RT (n = 41) P
6.72 ± 1.54 6.81 ± 1.65 <0.001
6.19 ± 1.32 6.27 ± 1.45 0.002
7.16 ± 1.12 6.91 ± 1.27 <0.001
6.87 ± 1.71 6.57 ± 1.83 <0.001
7.93 ± 2.29 7.83 ± 2.33 <0.001
6.73 ± 1.80 7.02 ± 1.80 <0.001
3.13 ± 2.37 3.44 ± 2.29 <0.001
6.62 ± 2.97 6.86 ± 2.92 0.042
8.04 ± 2.64 7.42 ± 2.81 0.148
6.06 ± 3.06 6.62 ± 3.20 <0.001
8.22 ± 2.39 7.46 ± 2.69 <0.001
Table 6 Change in scores and effect size after 28 days of









Function 7.90 ± 1.70 2.03 ± 0.87 (1.79, 2.27) 1.19
Emotion 7.03 ± 1.55 0.39 ± 0.77 (0.18, 0.60) 0.25
Family 7.69 ± 1.46 0.32 ± 0.65 (0.14, 0.50) 0.22
General 8.13 ± 1.56 0.52 ± 0.58 (0.36, 0.68) 0.33
Pain 8.08 ± 2.59 2.93 ± 1.09 (2.63, 3.23) 1.13
Swallow 8.00 ± 2.12 2.20 ± 0.99 (1.93, 2.47) 1.04
Saliva 5.24 ± 3.16 3.88 ± 1.92 (3.35, 4.41) 1.23
Appearance 7.56 ± 3.27 2.16 ± 0.98 (1.89, 2.43) 0.66
Speech 8.62 ± 2.38 1.00 ± 0.95 (0.74, 1.26) 0.42
Taste 7.40 ± 3.40 3.94 ± 1.66 (3.48, 4.40) 1.16
Cough 9.02 ± 1.89 2.18 ± 0.80 (1.96, 2.40) 1.15
aChange scores: −10 (maximum improvement) to +10 (maximum worsening).
bEffect size: calculated as change in scores divided by the SD of the
baseline score.
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the scale had good criterion validity. All domains (except the
speech domain) of the QOL-RTI/H&N were shown to be
sensitive to discriminate the QOL of HNC patients in differ-
ent RT stages (significantly different), which suggested the
scale had good discriminant validity. None of the domain
scores of HNC patients among different genders, other
chronic diseases, and tumor sites were significantly different.
These results were consistent with the hypothesis. The scale
was developed to measure QOL in HNC patients receiving
RT treatment. Therefore, it was not significantly associated
with gender, other chronic diseases or tumor site.
The sensitivity and responsiveness of the QOL-RTI/
H&N were confirmed. The HNC patients suffered nu-
merous symptoms, especially head and neck symptoms
after RT treatment, such as pain in the mouth and
throat, dry mouth, and speaking difficulties. Therefore,
the effect sizes of the function and H&N domains were
greater than those of emotion, family, and general do-
mains. Similar decreases in QOL were observed in the
English version, the Hong Kong version and the German
version of the scale [15,22,24]. The effect sizes of other
domains, except for emotion, family, general and speech
domains, were greater than 0.5. Therefore, the function
domain and the H&N module domains were considered
to be sufficiently clinically sensitive to reflect QOL
changes in HNC patients who received RT treatment.
In addition, the scale had good operability and accept-
ability. The response rate of the scale was 99.2% (238/
240). Most of the items had complete data. Item IRT23
“My sexual activity is satisfactory” had 16.0% missing
data, however. Chinese people usually feel embarrassed
to talk about their sexual activity or sexual life. The pa-
tients completed the scale in an average time of9.8 minutes. However, 4 patients said that the 0–10
Likert style scale was difficult to understand.
The study had some limitations. One is that all HNC
patients in the study were enrolled from the Cancer
Center of Sun Yat-sen University. Further assessment of
the QOL-RTI/H&N should be performed with results
from multiple centers to confirm the generalizability of
the findings. The second constraint is that a short test-
retest time interval (24 ~ 48 hours) was allowed in this
study. The short time interval may potentially cause the
overestimation of test-retest reliability. The third limita-
tion is that only 50 HNC patients were used to test the
responsiveness of the QOL-RTI/H&N scale. The respon-
siveness of the scale should be further assessed in a lar-
ger sample of patients.
Conclusions
The Chinese version of the QOL-RTI/H&N was trans-
lated according to the standard process for translating
instruments: a translation and back-translation proced-
ure, pilot testing and a validation study. The scale is
valid for measuring QOL in HNC patients with good re-
liability, validity and responsiveness. We recommend the
application of the QOL-RTI/H&N for measuring QOL
in HNC patients and assessing the effects of RT
treatment.
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